IRIX IRIDEX CORP
Electromedical & Electrotherapeutic Apparatus · Nasdaq · SEC CIK 1006045 · Fiscal year ends 01/03
Financial factors as of 2026-07-04 (2026Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY3.7%
TTM net income YoY34.9%
TTM EPS YoY37.5%
Revenue 3-yr CAGR-2.9%
Net income 3-yr CAGR—
Margins
Gross margin35.9%
Operating margin-5.4%
Net margin-6.9%
FCF margin-3.9%
EBITDA margin-4.5%
Returns
ROE-73.1%
ROA-12.1%
ROIC (approx.)—
Asset turnover1.75x
Leverage & solvency
Liabilities / assets86.6%
Debt / equity0.00x
Current ratio1.82x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.49x
Accruals ratio-6.2%
Payout ratio—
Capex / revenue0.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20262026-01-03 | FY20242024-12-28 | FY20232023-12-30 | FY20222022-12-31 | FY20212022-01-01 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $52.67M | $48.67M | $51.87M | $56.97M | $53.90M |
| Cost of revenue | $33.45M | $29.17M | $30.06M | $31.60M | $31.07M |
| Gross profit | $19.23M | $19.50M | $21.81M | $25.37M | $22.83M |
| R&D expense | $3.67M | $5.45M | $6.83M | $7.17M | $6.87M |
| SG&A expense | $7.73M | $9.78M | $8.75M | $7.56M | $8.86M |
| Operating income | -$2.57M | -$8.30M | -$10.01M | -$7.54M | -$7.53M |
| Interest expense | $58,000 | $146,000 | — | — | — |
| Pretax income | -$4.38M | -$8.84M | -$9.48M | -$7.48M | -$5.18M |
| Income tax | $57,000 | $68,000 | $90,000 | $65,000 | $40,000 |
| Net income | -$4.44M | -$8.91M | -$9.57M | -$7.55M | -$5.22M |
| EBITDA | -$2.05M | -$7.72M | -$8.91M | -$7.06M | -$6.73M |
| EPS (basic) | -0.26 | -0.54 | -0.59 | -0.47 | -0.34 |
| EPS (diluted) | -0.26 | -0.54 | -0.59 | -0.47 | -0.34 |
| Weighted avg. shares (diluted) | 16.93M | 16.44M | 16.13M | 15.94M | 15.42M |
| Balance sheet | |||||
| Cash & equivalents | $6.03M | $2.39M | $7.03M | $13.92M | $23.85M |
| Receivables | $7.61M | $5.95M | $6.73M | $6.23M | $6.61M |
| Inventory | $7.88M | $10.82M | $9.91M | $10.61M | $7.61M |
| Current assets | $25.25M | $23.56M | $27.45M | $35.77M | $42.25M |
| PP&E, net | $58,000 | $115,000 | $351,000 | $462,000 | $428,000 |
| Goodwill | $965,000 | $965,000 | $965,000 | $965,000 | $965,000 |
| Intangibles | $984,000 | $1.31M | $1.64M | $1.98M | $2.21M |
| Total assets | $29.15M | $29.14M | $34.44M | $42.29M | $48.69M |
| Current liabilities | $13.21M | $16.56M | $12.97M | $12.45M | $12.65M |
| Short-term debt | — | $1.70M | — | — | — |
| Long-term debt | — | $1.00M | — | — | — |
| Total debt | — | $2.70M | — | — | — |
| Total liabilities | $24.23M | $27.04M | $24.91M | $25.06M | $25.39M |
| Shareholders' equity | $4.92M | $2.10M | $9.52M | $17.23M | $23.30M |
| Net debt | — | $313,000 | — | — | — |
| Shares outstanding | 17.31M | 16.64M | 16.25M | 15.99M | 15.88M |
| Cash flow statement | |||||
| Operating cash flow | -$2.12M | -$7.29M | -$6.75M | -$9.52M | $8.22M |
| Capital expenditure | $143,000 | $13,000 | $109,000 | $286,000 | $213,000 |
| Free cash flow | -$2.26M | -$7.30M | -$6.85M | -$9.80M | $8.00M |
| Investing cash flow | -$143,000 | -$13,000 | -$109,000 | -$286,000 | -$5.56M |
| Financing cash flow | $5.96M | $2.60M | -$5,000 | -$73,000 | $9.47M |
| Depreciation & amortization | $523,000 | $584,000 | $1.10M | $485,000 | $803,000 |
| Stock-based compensation | $775,000 | $1.24M | $1.65M | $1.62M | $1.63M |
Free plan shows the latest 5 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.